Xiuying Zhang1, Chunfang Zhang2, Ling Chen1, Xueyao Han1, Linong Ji3. 1. Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Centre, Beijing, China. 2. Department of Clinical Epidemiology, Peking University People's Hospital, Beijing, China. 3. Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Centre, Beijing, China. Electronic address: jiln@bjmu.edu.cn.
Abstract
AIMS: To understand the relationship between serum acylcarnitine profiles and glucose tolerance status. METHODS: We analyzed 61 subjects who were divided into three groups based on their glucose tolerance status: normal glucose tolerance (NGT; n=20,M/F=9/11, mean age 48 years), pre-diabetes (Pre-DM; n=20,M/F=11/9, mean age 51 years), or newly diagnosed type 2 diabetes mellitus (T2DM; n=21,M/F=8/13, mean age 49 years). Fasting serum free carnitine and acylcarnitine concentrations were determined using isotope dilution electrospray ionization mass spectrometry coupled with high performance liquid chromatography. RESULTS: In comparison with NGT subjects, Pre-DM and type 2 diabetes subjects showed serum metabonomic changes highlighted by dysregulation of mitochondrial fatty acid combustion. Of the long-chain carnitine esters, significantly higher palmitoylcarnitine (C16), 3-OH-hexadecanoylcarnitine (C16-OH), carnitine C20, carnitine C22, and carnitine C24 concentrations (all P<0.05) were noted in the newly diagnosed type 2 diabetes group, and even the pre-diabetes group. CONCLUSIONS: This research provides further evidence of alterations in serum acylcarnitine profiles being associated with worse glucoseintolerance. The findings may suggest different degrees of involvement of dysregulated mitochondrial function and incomplete long-chain fatty acid oxidation pathways in the natural course of type 2 diabetes.
AIMS: To understand the relationship between serum acylcarnitine profiles and glucose tolerance status. METHODS: We analyzed 61 subjects who were divided into three groups based on their glucose tolerance status: normal glucose tolerance (NGT; n=20,M/F=9/11, mean age 48 years), pre-diabetes (Pre-DM; n=20,M/F=11/9, mean age 51 years), or newly diagnosed type 2 diabetes mellitus (T2DM; n=21,M/F=8/13, mean age 49 years). Fasting serum free carnitine and acylcarnitine concentrations were determined using isotope dilution electrospray ionization mass spectrometry coupled with high performance liquid chromatography. RESULTS: In comparison with NGT subjects, Pre-DM and type 2 diabetes subjects showed serum metabonomic changes highlighted by dysregulation of mitochondrial fatty acid combustion. Of the long-chain carnitine esters, significantly higher palmitoylcarnitine (C16), 3-OH-hexadecanoylcarnitine (C16-OH), carnitine C20, carnitine C22, and carnitine C24 concentrations (all P<0.05) were noted in the newly diagnosed type 2 diabetes group, and even the pre-diabetes group. CONCLUSIONS: This research provides further evidence of alterations in serum acylcarnitine profiles being associated with worse glucoseintolerance. The findings may suggest different degrees of involvement of dysregulated mitochondrial function and incomplete long-chain fatty acid oxidation pathways in the natural course of type 2 diabetes.
Authors: Julia Hernandez-Baixauli; Sergio Quesada-Vázquez; Roger Mariné-Casadó; Katherine Gil Cardoso; Antoni Caimari; Josep M Del Bas; Xavier Escoté; Laura Baselga-Escudero Journal: Nutrients Date: 2020-03-18 Impact factor: 5.717